Business
Precigen Reports Second Quarter and First Half 2020 Financial Results
- Announced proprietary electroporation device, UltraPorator™, designed to scale-up UltraCAR-T® manufacturing at multiple medical centers - - Announced
About this update from Precigen, Inc.
[{"type":"text","content":"- Announced proprietary electroporation device, UltraPorator™, designed to scale-up UltraCAR-T® manufacturing at multiple medical centers -\n - Announced positive topline results from Phase 1b study of AG019 ActoBiotics™ for type 1 diabetes -\n - Met primary endpoints of safety and feasibility in Phase I study of INXN-4001 for heart failure -\n - Guidance maintained for clinical readouts in 2020 -\n\n\nGERMANTOWN, Md., Aug. 10, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half financial results for 2020. \n\n \n \n \n \n \n \n\n \nBusiness Highlights:\nUltraPorator™: Precigen advanced the development of its proprietary electroporation device, UltraPorator™, including the initiation of both the manufacturing of a cGMP-compliant system and the process of technology transfer to its clinical sites. UltraPorator is a semi-closed, high-throughput system with a proprietary hardware and software solution designed to significantly reduce processing time and contamination risk, limitations of other electroporation devices and hurdles to the viable scale-up and commercialization of certain therapeutic programs. The Company expects to implement the system at multiple medical centers for the expansion phases of PRGN-3005, PRGN-3006 and the future UltraCAR-T clinical trials;PRGN-3005 UltraCAR-T®: Precigen initiated the dosing of patients in the third dose level of the intraperitoneal (IP) arm of the Phase 1 clinical trial of PRGN-3005 UltraCAR-T for treatment of advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer (clinical trial identifier: NCT03907527). Preclinical data for PRGN-3005 UltraCAR-T presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II demonstrated significantly superior expansion, persistence and preferred memory phenotype of UltraCAR-T in vivo and significantly superior efficacy in an ovarian cancer model compared to traditional CAR-T;AG019 ActoBiotics™: Precigen ActoBio, Inc., a wholly-owned subsidiary of Precigen, announced the Phase 1b monotherapy portion of the ongoing Phase 1b/2a clinical trial for investigational therapy AG019 ActoBiotics met the primary endpoint assess...